The effects of ubiquinone (CoQ10) on heart tissue in cardiac toxicity related to organophosphate poisoning.
The aim of this study was to examine the effects of ubiquinone (CoQ10) on heart tissue and erythrocytes in acute organophosphate poisoning (AOP). A total of 20 rabbits were divided into three groups: sham (n = 8), pralidoxime (PAM) + atropine (n = 6), and CoQ10 + PAM + atropine (n = 6). Blood samples were taken from each test subject to measure the values of acetylcholinesterase (AChE), nitric oxide (NO), and malondialdehyde (MDA) in the plasma and erythrocyte before administration of 50 mg/kg dichlorvos by orogastric tube. Blood samples were then taken at 1, 12, and 24 h post-dichlorvos to determine plasma and erythrocyte levels of AChE, NO, and MDA. Sham group received no treatment. PAM + atropine group received 0.05 mg/kg atropine with repeated doses and PAM: first a 30-mg/kg intravenous (IV) bolus, then a 15-mg/kg IV bolus every 4 h. CoQ10 + PAM + atropine group received same dose PAM and atropine and a 50-mg bolus of IV CoQ10. Thoracotomy was performed in all the animals 24 h after poisoning and then heart tissue samples were obtained. At 12 and 24 h, erythrocyte AChE levels in the CoQ10 animals were considerably higher than those in PAM + atropine animals (p = 0.023 and 0.017, respectively). At 12 and 24 h, erythrocyte MDA and NO levels in CoQ10 animals were significantly lower than those in PAM + atropine animals (p < 0.05). Heart tissue AChE levels in CoQ10 animals were considerably higher than those of the sham and PAM + atropine animals (p = 0.001). Heart tissue MDA and NO levels of CoQ10 animals were significantly lower than those of the sham and PAM + atropine animals (p < 0.01). Treatment of AOP with CoQ10 + PAM + atropine in this animal model had a beneficial effect on both erythrocyte and heart tissue lipid peroxidation and AChE activity.
Department of Emergency Medicine, Selçuk University, Konya, Turkey. aysegulbayir@hotmail.com
A
A
Bayir
H
H
Kara
O
O
Köylü
R
R
Kocabas
A
A
Ak
D000110:Acetylcholinesterase / Q000097:blood; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage*; D001285:Atropine / Q000008:administration & dosage*; D002801:Cholinesterase Reactivators / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D062025:Organophosphate Poisoning / Q000188:drug therapy* / Q000378:metabolism; D011220:Pralidoxime Compounds / Q000008:administration & dosage*; D011817:Rabbits; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000975:Antioxidants; D002801:Cholinesterase Reactivators; D011220:Pralidoxime Compounds; D014451:Ubiquinone; D009569:Nitric Oxide; D008315:Malondialdehyde; D001285:Atropine; D000110:Acetylcholinesterase; C024989:coenzyme Q10; C028797:pralidoxime